Response to treatment series: part 2, tumor response assessment--using new and conventional criteria.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 21701006.
- Also identified by DOI 10.2214/AJR.11.6581.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Conventional anatomic imaging biomarkers, including World Health Organization (WHO) criteria and Response Evaluation Criteria in Solid Tumors (RECIST), although effective, have limitations. This article will discuss the conventional and newer morphologic imaging biomarkers for the assessment of tumor response to therapy. Applying established methods of assessing tumor response to therapy allows consistency in image interpretation and facilitates communication with oncologists. Because of the new methods of treatment, assessment of necrosis and volumetric information will need to be incorporated into size-based criteria.
Medical subject headings
- Molecular Imaging
- Molecular Probe Techniques
- Neoplasms